Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles

Human Reproduction

Volumn 31, Issue 6, 2016, Pages 1253-1264

  Toftager, M ^a   Bogstad, J ^a   Bryndorf, T ^a   Lossl K ^a   Roskaer J ^b   Holland, T ^a   Praetorius L ^a   Zedeler, A ^a   Nilas, L ^a   Pinborg, A ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

GnRH agonist; GnRHantagonist; infertility; IVF; live birth rate; on going pregnancy rate; ovarian hyperstimulation syndrome; pregnancy rate

Indexed keywords

ALANINE AMINOTRANSFERASE; CHORIONIC GONADOTROPIN; CREATININE; GANIRELIX; NAFARELIN ACETATE; RECOMBINANT FOLLITROPIN; GONADORELIN;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANASARCA; ARTICLE; ASCITES; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DYSPNEA; EMBRYO; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; GESTATION PERIOD; GONADOTROPIN BLOOD LEVEL; HEMATOCRIT; HOSPITAL ADMISSION; HUMAN; HYDROTHORAX; INTENTION TO TREAT ANALYSIS; INTRACYTOPLASMIC SPERM INJECTION; KIDNEY FAILURE; LIVE BIRTH; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; OLIGURIA; OOCYTE RETRIEVAL; OPEN STUDY; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PHASE 4 CLINICAL TRIAL; PREGNANCY; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOEMBOLISM; TRANSVAGINAL ECHOGRAPHY; TREATMENT OUTCOME; VOMITING; AGONISTS; BLOOD; CLINICAL PROTOCOL; CLINICAL TRIAL; IN VITRO FERTILIZATION; INCIDENCE; PROCEDURES; RISK ASSESSMENT; TIME FACTOR;

CHORIONIC GONADOTROPIN; CLINICAL PROTOCOLS; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; INCIDENCE; LIVE BIRTH; OVARIAN HYPERSTIMULATION SYNDROME; PREGNANCY; PREGNANCY RATE; RISK ASSESSMENT; TIME FACTORS;

EID: 84973484129     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dew051     Document Type: Article

References (28)

1. Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update 2003;9:275-289.
2. Al-Inany H. GnRH antagonist in assisted reproduction: A Cochrane review. Hum Reprod 2002;17:874-885.
3. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: A Cochrane review. Reprod Biomed Online 2007;14:640-649.
4. Al-Inany HG, YoussefMA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J, Abou-Setta AM. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2011; CD001750.
5. Atkinson P, Koch J, LedgerWL. GnRHagonist trigger and a freeze-all strategy to prevent ovarian hyperstimulation syndrome: A retrospective study of OHSS risk and pregnancy rates. Aust N Z J Obstet Gynaecol 2014; 54:581-585.
6. Bentzen JG, Forman JL, Johannsen TH, Pinborg A, Larsen EC, Andersen AN. Ovarian antral follicle subclasses and anti-mullerian hormone during normal reproductive aging. J Clin Endocrinol Metab 2013;98:1602-1611.
7. Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod 2000;15:1490-1498.
8. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: A prospective randomized controlled study. Fertil Steril 2008;89:84-91.
9. Fleming R, Seifer DB, Frattarelli JL, Ruman J. Assessing ovarian response: Antral follicle count versus anti-Mullerian hormone. Reprod Biomed Online 2015;31:486-496.
10. Golan A, Weissman A. Symposium: Update on prediction and management of OHSS. A modern classification of OHSS. Reprod Biomed Online 2009; 19:28-32.
11. Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: An update review. Obstet Gynecol Surv 1989; 44:430-440.
12. Griesinger G, Schultz L, BauerT, Broessner A, FrambachT, Kissler S. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropinreleasing hormone antagonist protocol in combination with a 'freeze-all' strategy: A prospective multicentric study. Fertil Steril 2011;95:2029-2033, 2033 e2021.
13. Group EaMEOS. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001;16:644-651.
14. Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril 2010;94:389-400.
15. Humaidan P, Kol S, Papanikolaou EG, Copenhagen Gn RHATWG. GnRH agonist for triggering of final oocyte maturation: Time for a change of practice? Hum Reprod Update 2011;17:510-524.
16. Kolibianakis EM, Schultze-Mosgau A, Schroer A, van Steirteghem A, Devroey P, Diedrich K, Griesinger G. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 2005;20:2887-2892.
17. Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G. Amongpatients treated for IVF with gonadotrophins andGnRHanalogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update 2006; 12:651-671.
18. Kumar P, Sait SF, Sharma A, Kumar M. Ovarian hyperstimulation syndrome. J Hum Reprod Sci 2011;4:70-75.
19. Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, LainasGT, Alexopoulou E, Kolibianakis EM. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: A prospective randomised controlled trial (RCT). Hum Reprod 2010; 25:83-689.
20. Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000; 73:901-907.
21. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992; 58:249-261.
22. Papanikolaou EG, Tournaye H, Verpoest W, Camus M, Vernaeve V, Van Steirteghem A, Devroey P. Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum Reprod 2005; 20:636-641.
23. Papanikolaou EG, Pozzobon C, Kolibianakis EM, Camus M, Tournaye H, Fatemi HM, Van Steirteghem A, Devroey P. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropinreleasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006; 85:112-120.
24. Practice Committee of American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril 2008;90:S188-S193.
25. Prapas Y, Petousis S, Dagklis T, Panagiotidis Y, Papatheodorou A, Assunta I, Prapas N. GnRHantagonist versus longGnRHagonist protocol in poor IVF responders: A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 2013;166:43-46.
26. Rabau E, David A, Serr DM, Mashiach S, Lunenfeld B. Human menopausal gonadotropins for anovulation and sterility. Results of 7 years of treatment. Am J Obstet Gynecol 1967;98:92-98.
27. Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome: A current survey. Fertil Steril 1978;30:255-268.
28. Xiao JS, Su CM, Zeng XT. Comparisons of GnRH antagonist versus GnRH agonist protocol in supposed normal ovarian responders undergoing IVF: A systematic review and meta-analysis. PLoS One 2014;9:e106854.